Exploring Emerging Markets in NeuroOncology

The multinational market for brain cancer was valued at $500 million in 2012 and is expect to reach $1.1 billion by 2017, at a CAGR of 12.5%. Considerations like increased scope of neurological & immunological studies, clinical trials; rise in awareness for health & government and institution funds for research have exceedingly furnished for the ascending claim for the neuro oncologists, neurologists market. North America is the market leader with a share of ~40% of the global market, followed by Europe with a share of ~38%. The presence of a large number of analytical equipment manufacturers has contributed significantly to the North American and European metabolomics market. Yet the Asia-Pacific sector renders a momentous development possibility for the neurology & Oncologists emporium through the prognosis period of 2015 to 2019. 

http://neurooncology.conferenceseries.com/